Click for best price
Orphan Drugs Market Size, Share 2022
Market Analysis and Insights: Global Orphan Drugs Market
The global Orphan Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Orphan Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Orphan Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Orphan Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Orphan Drugs market.
Global Orphan Drugs Scope and Market Size
Orphan Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Orphan Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Orphan Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic Disorders
Endocrinology
Infectious Diseases
Others
Segment by Application
Hospital Pharmacies
Retail pharmacies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novartis
Bristol-Myers Squibb Company
Celgene
F. Hoffmann-La Roche
Pfizer
Sanofi
Alexion Pharmaceuticals
Eli Lilly and Company
Novo Nordisk
AstraZeneca
Eisai
Daiichi Sankyo Company
Bayer
GlaxoSmithKline
Merck & Co
Johnson & Johnson
Biogen
Takeda
Amgen
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Orphan Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Orphan Drugs, with price, sales, revenue, and global market share of Orphan Drugs from 2019 to 2022.
Chapter 3, the Orphan Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Orphan Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Orphan Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Orphan Drugs.
Chapter 13, 14, and 15, to describe Orphan Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Orphan Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Orphan Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
111 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Orphan Drugs Product Introduction
1.2 Global Orphan Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Orphan Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Orphan Drugs Sales in Volume for the Year 2017-2028
1.3 United States Orphan Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Orphan Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Orphan Drugs Sales in Volume for the Year 2017-2028
1.4 Orphan Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Orphan Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Orphan Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Orphan Drugs Market Dynamics
1.5.1 Orphan Drugs Industry Trends
1.5.2 Orphan Drugs Market Drivers
1.5.3 Orphan Drugs Market Challenges
1.5.4 Orphan Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Orphan Drugs Market Segment by Type
2.1.1 Oncology
2.1.2 Gastrointestinal
2.1.3 Pulmonary
2.1.4 Neurology
2.1.5 Hematology
2.1.6 Cardio-vascular
2.1.7 Metabolic Disorders
2.1.8 Endocrinology
2.1.9 Infectious Diseases
2.1.10 Others
2.2 Global Orphan Drugs Market Size by Type
2.2.1 Global Orphan Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Orphan Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Orphan Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Orphan Drugs Market Size by Type
2.3.1 United States Orphan Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Orphan Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Orphan Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Orphan Drugs Market Segment by Application
3.1.1 Hospital Pharmacies
3.1.2 Retail pharmacies
3.1.3 Others
3.2 Global Orphan Drugs Market Size by Application
3.2.1 Global Orphan Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Orphan Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Orphan Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Orphan Drugs Market Size by Application
3.3.1 United States Orphan Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Orphan Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Orphan Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Orphan Drugs Competitor Landscape by Company
4.1 Global Orphan Drugs Market Size by Company
4.1.1 Top Global Orphan Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Orphan Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Orphan Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Orphan Drugs Price by Manufacturer (2017-2022)
4.2 Global Orphan Drugs Concentration Ratio (CR)
4.2.1 Orphan Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Orphan Drugs in 2021
4.2.3 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Orphan Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Orphan Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Orphan Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Orphan Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Orphan Drugs Market Size by Company
4.5.1 Top Orphan Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Orphan Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Orphan Drugs Sales by Players (2020, 2021 & 2022)
5 Global Orphan Drugs Market Size by Region
5.1 Global Orphan Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Orphan Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Orphan Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Orphan Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Orphan Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Orphan Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Orphan Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Orphan Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Orphan Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Orphan Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Orphan Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Orphan Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Orphan Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Orphan Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Orphan Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Orphan Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Orphan Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Corporation Information
7.1.2 Novartis Description and Business Overview
7.1.3 Novartis Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Novartis Orphan Drugs Products Offered
7.1.5 Novartis Recent Development
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Corporation Information
7.2.2 Bristol-Myers Squibb Company Description and Business Overview
7.2.3 Bristol-Myers Squibb Company Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Bristol-Myers Squibb Company Orphan Drugs Products Offered
7.2.5 Bristol-Myers Squibb Company Recent Development
7.3 Celgene
7.3.1 Celgene Corporation Information
7.3.2 Celgene Description and Business Overview
7.3.3 Celgene Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Celgene Orphan Drugs Products Offered
7.3.5 Celgene Recent Development
7.4 F. Hoffmann-La Roche
7.4.1 F. Hoffmann-La Roche Corporation Information
7.4.2 F. Hoffmann-La Roche Description and Business Overview
7.4.3 F. Hoffmann-La Roche Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 F. Hoffmann-La Roche Orphan Drugs Products Offered
7.4.5 F. Hoffmann-La Roche Recent Development
7.5 Pfizer
7.5.1 Pfizer Corporation Information
7.5.2 Pfizer Description and Business Overview
7.5.3 Pfizer Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Pfizer Orphan Drugs Products Offered
7.5.5 Pfizer Recent Development
7.6 Sanofi
7.6.1 Sanofi Corporation Information
7.6.2 Sanofi Description and Business Overview
7.6.3 Sanofi Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Sanofi Orphan Drugs Products Offered
7.6.5 Sanofi Recent Development
7.7 Alexion Pharmaceuticals
7.7.1 Alexion Pharmaceuticals Corporation Information
7.7.2 Alexion Pharmaceuticals Description and Business Overview
7.7.3 Alexion Pharmaceuticals Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Alexion Pharmaceuticals Orphan Drugs Products Offered
7.7.5 Alexion Pharmaceuticals Recent Development
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Corporation Information
7.8.2 Eli Lilly and Company Description and Business Overview
7.8.3 Eli Lilly and Company Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Eli Lilly and Company Orphan Drugs Products Offered
7.8.5 Eli Lilly and Company Recent Development
7.9 Novo Nordisk
7.9.1 Novo Nordisk Corporation Information
7.9.2 Novo Nordisk Description and Business Overview
7.9.3 Novo Nordisk Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Novo Nordisk Orphan Drugs Products Offered
7.9.5 Novo Nordisk Recent Development
7.10 AstraZeneca
7.10.1 AstraZeneca Corporation Information
7.10.2 AstraZeneca Description and Business Overview
7.10.3 AstraZeneca Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 AstraZeneca Orphan Drugs Products Offered
7.10.5 AstraZeneca Recent Development
7.11 Eisai
7.11.1 Eisai Corporation Information
7.11.2 Eisai Description and Business Overview
7.11.3 Eisai Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Eisai Orphan Drugs Products Offered
7.11.5 Eisai Recent Development
7.12 Daiichi Sankyo Company
7.12.1 Daiichi Sankyo Company Corporation Information
7.12.2 Daiichi Sankyo Company Description and Business Overview
7.12.3 Daiichi Sankyo Company Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Daiichi Sankyo Company Products Offered
7.12.5 Daiichi Sankyo Company Recent Development
7.13 Bayer
7.13.1 Bayer Corporation Information
7.13.2 Bayer Description and Business Overview
7.13.3 Bayer Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Bayer Products Offered
7.13.5 Bayer Recent Development
7.14 GlaxoSmithKline
7.14.1 GlaxoSmithKline Corporation Information
7.14.2 GlaxoSmithKline Description and Business Overview
7.14.3 GlaxoSmithKline Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 GlaxoSmithKline Products Offered
7.14.5 GlaxoSmithKline Recent Development
7.15 Merck & Co
7.15.1 Merck & Co Corporation Information
7.15.2 Merck & Co Description and Business Overview
7.15.3 Merck & Co Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Merck & Co Products Offered
7.15.5 Merck & Co Recent Development
7.16 Johnson & Johnson
7.16.1 Johnson & Johnson Corporation Information
7.16.2 Johnson & Johnson Description and Business Overview
7.16.3 Johnson & Johnson Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Johnson & Johnson Products Offered
7.16.5 Johnson & Johnson Recent Development
7.17 Biogen
7.17.1 Biogen Corporation Information
7.17.2 Biogen Description and Business Overview
7.17.3 Biogen Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Biogen Products Offered
7.17.5 Biogen Recent Development
7.18 Takeda
7.18.1 Takeda Corporation Information
7.18.2 Takeda Description and Business Overview
7.18.3 Takeda Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Takeda Products Offered
7.18.5 Takeda Recent Development
7.19 Amgen
7.19.1 Amgen Corporation Information
7.19.2 Amgen Description and Business Overview
7.19.3 Amgen Orphan Drugs Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Amgen Products Offered
7.19.5 Amgen Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Orphan Drugs Industry Chain Analysis
8.2 Orphan Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Orphan Drugs Distributors
8.3 Orphan Drugs Production Mode & Process
8.4 Orphan Drugs Sales and Marketing
8.4.1 Orphan Drugs Sales Channels
8.4.2 Orphan Drugs Distributors
8.5 Orphan Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Orphan Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Orphan Drugs Market Trends
Table 3. Orphan Drugs Market Drivers
Table 4. Orphan Drugs Market Challenges
Table 5. Orphan Drugs Market Restraints
Table 6. Global Orphan Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Orphan Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Orphan Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Orphan Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Orphan Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Orphan Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Orphan Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Orphan Drugs Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Orphan Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Orphan Drugs Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Orphan Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Orphan Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Drugs as of 2021)
Table 18. Top Players of Orphan Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Orphan Drugs Product Type
Table 20. Date of International Manufacturers Enter into Orphan Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Orphan Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Orphan Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Orphan Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Orphan Drugs Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Orphan Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Orphan Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Orphan Drugs Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Orphan Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Orphan Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Orphan Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Orphan Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Orphan Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Orphan Drugs Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Orphan Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Orphan Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Orphan Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Orphan Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Orphan Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Orphan Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Orphan Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Novartis Corporation Information
Table 43. Novartis Description and Business Overview
Table 44. Novartis Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Novartis Orphan Drugs Product
Table 46. Novartis Recent Development
Table 47. Bristol-Myers Squibb Company Corporation Information
Table 48. Bristol-Myers Squibb Company Description and Business Overview
Table 49. Bristol-Myers Squibb Company Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Bristol-Myers Squibb Company Product
Table 51. Bristol-Myers Squibb Company Recent Development
Table 52. Celgene Corporation Information
Table 53. Celgene Description and Business Overview
Table 54. Celgene Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Celgene Product
Table 56. Celgene Recent Development
Table 57. F. Hoffmann-La Roche Corporation Information
Table 58. F. Hoffmann-La Roche Description and Business Overview
Table 59. F. Hoffmann-La Roche Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. F. Hoffmann-La Roche Product
Table 61. F. Hoffmann-La Roche Recent Development
Table 62. Pfizer Corporation Information
Table 63. Pfizer Description and Business Overview
Table 64. Pfizer Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Pfizer Product
Table 66. Pfizer Recent Development
Table 67. Sanofi Corporation Information
Table 68. Sanofi Description and Business Overview
Table 69. Sanofi Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Sanofi Product
Table 71. Sanofi Recent Development
Table 72. Alexion Pharmaceuticals Corporation Information
Table 73. Alexion Pharmaceuticals Description and Business Overview
Table 74. Alexion Pharmaceuticals Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Alexion Pharmaceuticals Product
Table 76. Alexion Pharmaceuticals Recent Development
Table 77. Eli Lilly and Company Corporation Information
Table 78. Eli Lilly and Company Description and Business Overview
Table 79. Eli Lilly and Company Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. Eli Lilly and Company Product
Table 81. Eli Lilly and Company Recent Development
Table 82. Novo Nordisk Corporation Information
Table 83. Novo Nordisk Description and Business Overview
Table 84. Novo Nordisk Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Novo Nordisk Product
Table 86. Novo Nordisk Recent Development
Table 87. AstraZeneca Corporation Information
Table 88. AstraZeneca Description and Business Overview
Table 89. AstraZeneca Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. AstraZeneca Product
Table 91. AstraZeneca Recent Development
Table 92. Eisai Corporation Information
Table 93. Eisai Description and Business Overview
Table 94. Eisai Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 95. Eisai Product
Table 96. Eisai Recent Development
Table 97. Daiichi Sankyo Company Corporation Information
Table 98. Daiichi Sankyo Company Description and Business Overview
Table 99. Daiichi Sankyo Company Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 100. Daiichi Sankyo Company Product
Table 101. Daiichi Sankyo Company Recent Development
Table 102. Bayer Corporation Information
Table 103. Bayer Description and Business Overview
Table 104. Bayer Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 105. Bayer Product
Table 106. Bayer Recent Development
Table 107. GlaxoSmithKline Corporation Information
Table 108. GlaxoSmithKline Description and Business Overview
Table 109. GlaxoSmithKline Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 110. GlaxoSmithKline Product
Table 111. GlaxoSmithKline Recent Development
Table 112. Merck & Co Corporation Information
Table 113. Merck & Co Description and Business Overview
Table 114. Merck & Co Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 115. Merck & Co Product
Table 116. Merck & Co Recent Development
Table 117. Johnson & Johnson Corporation Information
Table 118. Johnson & Johnson Description and Business Overview
Table 119. Johnson & Johnson Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 120. Johnson & Johnson Product
Table 121. Johnson & Johnson Recent Development
Table 122. Biogen Corporation Information
Table 123. Biogen Description and Business Overview
Table 124. Biogen Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 125. Biogen Product
Table 126. Biogen Recent Development
Table 127. Takeda Corporation Information
Table 128. Takeda Description and Business Overview
Table 129. Takeda Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 130. Takeda Product
Table 131. Takeda Recent Development
Table 132. Amgen Corporation Information
Table 133. Amgen Description and Business Overview
Table 134. Amgen Orphan Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 135. Amgen Product
Table 136. Amgen Recent Development
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Orphan Drugs Customers List
Table 140. Orphan Drugs Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Orphan Drugs Product Picture
Figure 2. Global Orphan Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Orphan Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Orphan Drugs Sales 2017-2028 (K Units)
Figure 5. United States Orphan Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Orphan Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Orphan Drugs Sales 2017-2028 (K Units)
Figure 8. United States Orphan Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Orphan Drugs Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Orphan Drugs Report Years Considered
Figure 11. Product Picture of Oncology
Figure 12. Product Picture of Gastrointestinal
Figure 13. Product Picture of Pulmonary
Figure 14. Product Picture of Neurology
Figure 15. Product Picture of Hematology
Figure 16. Product Picture of Cardio-vascular
Figure 17. Product Picture of Metabolic Disorders
Figure 18. Product Picture of Endocrinology
Figure 19. Product Picture of Infectious Diseases
Figure 20. Product Picture of Others
Figure 21. Global Orphan Drugs Market Share by Type in 2022 & 2028
Figure 22. Global Orphan Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 23. Global Orphan Drugs Sales Market Share in Value by Type (2017-2028)
Figure 24. Global Orphan Drugs Sales by Type (2017-2028) & (K Units)
Figure 25. Global Orphan Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 26. Global Orphan Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 27. United States Orphan Drugs Market Share by Type in 2022 & 2028
Figure 28. United States Orphan Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 29. United States Orphan Drugs Sales Market Share in Value by Type (2017-2028)
Figure 30. United States Orphan Drugs Sales by Type (2017-2028) & (K Units)
Figure 31. United States Orphan Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 32. United States Orphan Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 33. Product Picture of Hospital Pharmacies
Figure 34. Product Picture of Retail pharmacies
Figure 35. Product Picture of Others
Figure 36. Global Orphan Drugs Market Share by Application in 2022 & 2028
Figure 37. Global Orphan Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. Global Orphan Drugs Sales Market Share in Value by Application (2017-2028)
Figure 39. Global Orphan Drugs Sales by Application (2017-2028) & (K Units)
Figure 40. Global Orphan Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 41. Global Orphan Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 42. United States Orphan Drugs Market Share by Application in 2022 & 2028
Figure 43. United States Orphan Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 44. United States Orphan Drugs Sales Market Share in Value by Application (2017-2028)
Figure 45. United States Orphan Drugs Sales by Application (2017-2028) & (K Units)
Figure 46. United States Orphan Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 47. United States Orphan Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 48. North America Orphan Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 49. North America Orphan Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 50. U.S. Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Canada Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Europe Orphan Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 53. Europe Orphan Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 54. Germany Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. France Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. U.K. Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Italy Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Russia Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Asia-Pacific Orphan Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 60. Asia-Pacific Orphan Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 61. China Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Japan Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. South Korea Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. India Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Australia Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Taiwan Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Indonesia Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Thailand Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Malaysia Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Philippines Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Latin America Orphan Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 72. Latin America Orphan Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 73. Mexico Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Brazil Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Argentina Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. Middle East & Africa Orphan Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 77. Middle East & Africa Orphan Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 78. Turkey Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 79. Saudi Arabia Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 80. U.A.E Orphan Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 81. Orphan Drugs Value Chain
Figure 82. Orphan Drugs Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
